Product Images Faslodex
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 16 images provide visual information about the product associated with Faslodex NDC 0310-0720 by Astrazeneca Pharmaceuticals Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure14
Figure 1 - Figure 1
Figure 10 - Figure 10
This appears to be a graph or table showing the Overall Survival Probability (%) and the number of patients at risk over a period of 54 months. The comparison is between two groups, one receiving FASLODEX with palbociclib and the other receiving FASLODEX with placebo. The survival times are shown in months from time 0 to 54 months. There is more data in the table, but due to the formatting, does not provide accurate details.*
Figure 11
This is a graph that shows the progression-free survival probability (%) for two groups of patients - one group received FASLODEX plus Abemaciclib treatment (N=446) and the other group received FASLODEX plus Placebo (N=223). The survival probability is indicated on the y-axis and the months are indicated on the x-axis. The number of patients at risk is also indicated on the x-axis for each time point.*
Figure 12
This is a graph displaying the survival rates of patients who were given FASLODEX plus Abemaciclib versus FASLODEX plus Placebo over a period of 57 months. There were 446 patients in the FASLODEX plus Abemaciclib group and 223 in the FASLODEX plus Placebo group. The y-axis represents the percentage of patients still alive, and the x-axis represents the time in months. The survival rate of the FASLODEX plus Abemaciclib group is consistently higher than the survival rate of the FASLODEX plus Placebo group.*
Figure 2 - Figure 2
Figure 3 - Figure 3
Figure 4 - Figure 4
Figure 5 - Figure 5
Figure 6
This appears to be a graph or chart showing the progression-free survival over time for patients. The graph displays the terms "Progression Free Survival," "ITT Population," "FASLODEX 250mg," and "FASLODEX 500mg." The x-axis shows time in months, with up to 45 months shown. The y-axis displays values ranging from 0 to 1.0, with increments of 0.1 labeled. There appears to be two lines, one labeled "FASLODEX 250mg," and the other labeled "FASLODEX 500mg," each showing a curve for progression-free survival over time. The graph also displays numbers at risk for each group at different points in time. A more detailed description of the graph cannot be provided based on this limited and incomplete text.*
Figure 7
This is a graph showing the proportion of patients who were alive over time while taking either FASLODEX 500mg or FASLODEX 250mg. The time frame is over 80 months and it appears that there is no statistically significant difference between the two doses, but adjustments were not made for multiplicity. The number of patients at risk for each dose at each time point is also shown.*
Figure 8
Figure 9
This is a clinical study that compares the efficacy of FASLODEX with and without palbociclib in terms of progression-free survival. The text includes a graph that shows the probability of progression-free survival over time for each treatment option. The results suggest that FASLODEX combined with palbociclib has a higher probability of progression-free survival compared to FASLODEX with a placebo.*
NDC0310 0720 10
chemical structure Faslodex - chemical structure Faslodex
figure12
This appears to be a graph showing censoring times for two different treatments (FASLODEX with Ribociclib and FASLODEX with Placebo). The graph shows the percentage of patients still at risk over a period of 26 months, with the number of patients still at risk also displayed. The number of patients still at risk decreases over time for both treatments.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
